Comparison of CA 125 after three courses of chemotherapy and results of second-look surgery

European Journal of Gynaecological Oncology

Volumn 21, Issue 1, 2000, Pages 70-73

  Wong, C ^a   Meltem Dai, Z ^b   Lele, Shashikant B ^a   Natarajan, N ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b FATIH UNIVERSITY MEDICAL SCHOOL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PACLITAXEL;

ADULT; ARTICLE; CANCER STAGING; CHEMOTHERAPY; CLINICAL FEATURE; COMPARATIVE STUDY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PHYSICAL EXAMINATION; PREDICTION; SECOND LOOK SURGERY; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REOPERATION; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 0033950075     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Young R. C., Decker D. G., Wharton J. T. et al: "Staging laparotomy in early ovarian cancer". JAMA, 1983, 250, 3072.
2. McGuire W. P., Hoskins W. J., Brady M. F., Kucera P. R., Partridge E. E., Look K. J., Clarke-Pearson D., Davidson M.: "Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer". N. Engl. J. Med., 1996, 334, 1.
3. Thigpen J. T., Vance R. B., Khansur T.: "Second-line chemotherapy for recurrent carcinoma of the ovary". Cancer, 1993, 71, 1559.
4. van der Burg M. E. L., Lammes F. B., van Putten W. L. J., Stoter G.: "Ovarian cancer: the prognostic value of the serum half-life of CA 125 during induction chemotherapy". Gynecol. Oncol., 1988, 30, 307.
5. Lavin P. T., Knapp R. C., Malkasian O., Whitney C. W., Berek J. C., Bast R. C.: "CA 125 for the monitoring of ovarian carcinoma during primary therapy". Obstet. Gynecol., 1987, 69, 223.
6. Stehman F. B., Calkins A. R., Wass J. L., Smirz L. R., Sutton G. P., Ehrlich C. E.: "A comparison of findings at second-look laparotomy with preoperative computed tomography in patients with ovarian cancer". Gynecol. Oncol., 1988, 29, 37.
7. Cancer Committee of the International Federation of Gynecology and Obstetrics: "Staging Announcement FIGO Cancer Committee". Gynecol. Oncol., 1986, 25, 383.
8. Kaplan E. L., Meier R.: "Nonparametric estimations from incomplete observations". J. Am. Stat. Assoc., 1958, 53, 475.
9. Peto R., Peto J.: "Asymptomatically efficient rank invariant test procedures". J. R. Stat. Soc. (A), 1972, 135, 185.
10. Neijt J. P., ten Bokkel Huinink W. W., van der Burg M. E., van Osterom A. T., Willemse P. H., Heintz A. P., van Lent M. et al.: "Randomized trial comparing two combination chemotherapy regimens (CHAP-5 vs CP) in advanced ovarian carcinoma". J. Clin. Oncol., 1987, 5, 1157.
11. The Ovarian Cancer Meta-Analysis Group: "Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis". J. Clin. Oncol., 1991, 9, 1668.
12. Smith J. P., Delgado G., Rutledge F.: "Second-look operation in ovarian carcinoma". Cancer, 1976, 38, 1438.
13. Chambers S. K., Chambers J. T., Kohorn E. I., Lawrence R., Schwartz P. E.: "Evaluation of the role of second-look surgery in ovarian cancer". Obstet. Gynecol., 1988, 72, 404.
14. Hempling R. E., Wesolowski J. A., Piver M. S.: "Second-look laparotomy in advanced ovarian cancer: a critical assessment of morbidity and impact on survival". Ann. Surg. Oncol., 1997, 4, 349.
15. Tuxen M. K., Strauss G., Lund B., Hansen M.: "The role of second-look laparotomy in the long-term survival in ovarian cancer". Ann. Oncol., 1997, 8, 643.
16. Gadducci A., Sartori E., Maggino T., Zola P., Landoni F., Fanucchi A., Palai N. et al.: "Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study". Gynecol. Oncol., 1998, 68, 150.
17. Cohen C. J., Goldberg J. D., Holland J. F., Bruchner H. W. et al: "Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO stages III and IV) as measured by surgical end-staging (second-look operations)". Am. J. Obstet. Gynecol., 1983, 145, 955.
18. Clarke-Pearson D. L., Bandy L. C., Dudzinski M., Heaston D., Creasman W. T.: "Computed tomography in evaluation of patients with ovarian carcinoma in complete clinical remission". JAMA, 1986, 255, 627.
19. De Rosa V., Mangoni Di Stefano M. L., Brunetti A., Caraco C, Graziano R., Gallo M. S., Maffeo A.: "Computed tomography and second-look surgery in ovarian cancer patients. Correlation, actual role and limitations of CT scan". Eur. J. Gynaec. Oncol., 1995, 6, 123.
20. Mogensen O., Mogensen B., Jakobsen A., Sell A.: "Measurement of ovarian cancer-associated antigen CA 125 prior to second-look operation". Gynecol. Oncol., 1990, 37, 44.
21. Potter M. E., Moradi M., To A. C. W., Hatch K. D., Shingleton H. M.: "Value of serum CA 125 levels: does the result preclude second -look?". Gynecol. Oncol., 1989, 33, 201.
22. Hording U., Toftager-Larsen K., Lund B., Dreisler A., Daugaard S., Lundvall F. et al.: "The value of CA 125 measurement before second-look laparotomy in patients with ovarian carcinoma". Eur. J. Gynaec. Oncol., 1994, 15, 217.
23. Rubin S. C., Hoskins W. J., Hakes T. B., Markman M., Reichman B. S., Chapman D., Lewis J. L.: "Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer". Am. J. Obstet. Gynecol., 1989, 160, 667.
24. Pastner B., Orr J. W., Mann W. J., Taylor P. T., Partridge E., Allmen T: "Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?". Gynecol. Oncol., 1990, 37, 319.
25. Redman C. W. E., Blackledge G. R., Kelly K., Powell J., Buxton E. J., Luesley D. M.: "Early serum CA 125 response and outcome in epithelial ovarian cancer". Eur. J. Cancer, 1990, 26, 593.